

**Contact: Andrew Krouse**  
(434) 974-6969  
krouse@tautherapeutics.com  
[www.tautherapeutics.com](http://www.tautherapeutics.com)

**Tau Therapeutics Raises \$3.55MM to Support Research**  
*Study results will advance Tau's novel cancer therapies and NCEs*

(Charlottesville, VA) Tau Therapeutics LLC (also doing business as [Cavion](#)), a clinical stage oncology company repositioning and developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has closed a \$3.55 million round of private equity financing. The proceeds will support Tau's [ongoing clinical trial](#) with the National Cancer Institute's Adult Brain Tumor Consortium (ABTC), preclinical studies at several institutions, and a robust new chemical entity development program. Tau has raised over \$13 million from private investors throughout the United States and received over \$12 million in non-dilutive resources in the last eight years.

"This is a very exciting time for us as we continue to test our therapy in brain cancer patients and to explore the effectiveness of T-type calcium channel inhibitors in other solid tumor cancers," said President and CEO Andrew Krouse. "Although our lead drug, mibefradil, has been successful in providing proof of concept, we are also working to develop follow on compounds with improved efficacy, safety and target selectivity." In addition to the ABTC trial, a new [trial at Yale University](#) will test mibefradil's ability to increase cancer's vulnerability to radiation therapy.

**About Tau Therapeutics LLC**

Tau Therapeutics (also doing business as [Cavion](#)), is a clinical stage, private biotechnology company ushering in a new class of oncology drugs for solid tumors. From its drug discovery platform, Tau is developing new chemical entities that control the cell cycle by selectively inhibiting the T-type calcium channel – Cav3. Tau's proprietary knowledge of Cav3 and its ability to develop tailored T-type calcium channel blockers offer a non-toxic and potentially indispensable addition to emerging chemotherapy cocktails.

Tau is conducting a multi-site [NCI Adult Brain Tumor Consortium-sponsored Phase 1b clinical trial](#) of the T-type calcium channel blocker mibefradil administered with temozolomide in brain cancer and [A Yale University-sponsored Phase 1](#) trial of mibefradil combined with hypofractionated radiation therapy.

**Forward-Looking Statement**

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Tau Therapeutics LLC disclaims any intent or obligation to update forward-looking statements, except as required by law.